Maxim Group Reiterates a Buy Rating on Cytosorbents CorpBy Carrie Williams
“CytoSorbents issued a letter to its shareholders today highlighting the progress the company achieved in 2016.”
According to TipRanks.com, Zhou is a 1-star analyst with an average return of -3.6% and a 29.7% success rate. Zhou covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sciclone Pharmaceuticals, and Mateon Therapeutics Inc.
Cytosorbents Corp has an analyst consensus of Moderate Buy.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CTSO in relation to earlier this year. Most recently, in December 2016, Phillip Chan, the President & CEO of CTSO bought 4,600 shares for a total of $24,840.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. is a critical care immunotherapy company, which engages in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. Its products include cytosorb, contrastsorb, vetresq, hemodefend, and drugsorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.